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Abstract: We explored the contribution of nitrosamine metabolism to lung cancer in a 
pilot investigation of genetic variation in CYP2B6, a high-affinity enzymatic activator of 
tobacco-specific nitrosamines with a negligible role in nicotine metabolism. Previously we 
found that variation in CYP2A6 and CHRNA5-CHRNA3-CHRNB4 combined to increase 
lung cancer risk in a case-control study in European American ever-smokers (n = 860). 
However, these genes are involved in the pharmacology of both nicotine, through which 
they alter smoking behaviours, and carcinogenic nitrosamines. Herein, we separated 
participants by CYP2B6 genotype into a high- vs. low-risk group (*1/*1 + *1/*6 vs. *6/*6). 
Odds ratios estimated through logistic regression modeling were 1.25 (95% CI 0.68–2.30), 
1.27 (95% CI 0.89–1.79) and 1.56 (95% CI 1.04–2.31) for CYP2B6, CYP2A6 and 
CHRNA5-CHRNA3-CHRNB4, respectively, with negligible differences when all genes 
were evaluated concurrently. Modeling the combined impact of high-risk genotypes 
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yielded odds ratios that rose from 2.05 (95% CI 0.39–10.9) to 2.43 (95% CI 0.47–12.7) to 
3.94 (95% CI 0.72–21.5) for those with 1, 2 and 3 vs. 0 high-risk genotypes, respectively. 
Findings from this pilot point to genetic variation in CYP2B6 as a lung cancer risk factor 
supporting a role for nitrosamine metabolic activation in the molecular mechanism of  
lung carcinogenesis. 
Keywords: CYP2B6; CYP2A6; CHRNA5-CHRNA3-CHRNB4; tobacco specific 
nitrosamines; lung cancer risk; genetic variation 
 
1. Introduction 
Variation in genes participating in nicotine and nitrosamine pharmacology has been associated with 
lung cancer risk among smokers. We have reported that variation in the nicotine and  
nitrosamine metabolizing gene, CYP2A6, and the nicotinic receptor subunit gene cluster,  
CHRNA5-CHRNA3-CHRNB4 (CHRNA5-A3-B4), combined to increase cigarette consumption and 
lung cancer risk among European American cigarette smokers [1]. Owing to the contribution of these 
genes to nicotine pharmacology, CYP2A6 and CHRNA5-A3-B4 increase lung cancer risk indirectly 
through increased cigarette consumption and thus increased carcinogen exposure. Additionally,  
these genes could be contributing to lung cancer risk directly through altered nitrosamine  
pharmacology—the CYP2A6 enzyme metabolically activates tobacco specific nitrosamines  
(TSNA) [2] and the nicotinic receptors are high-affinity binding sites for nitrosamines [3]. 
To explicitly explore the potential contribution of altered nitrosamine pharmacology to lung cancer 
risk among smokers, we have extended our investigation of gene variants to CYP2B6. CYP2B6, like 
CYP2A6, is expressed in the lung in addition to the liver [4,5] and metabolically activates TSNAs to 
DNA-reactive products [2,6]. Enzymatic activation of the potent lung procarcinogenic TSNA,  
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), has been linked to NNK-induced lung  
tumors [7], and the CYP2B6 enzyme has a high affinity for NNK [8]—roughly ten-fold higher 
compared to CYP2A6 [6]. CYP2A6, on the other hand, has a higher affinity for the TSNA,  
N'-nitrosonornicotine (NNN), than for NNK [6,9] and may preferentially metabolize NNN while 
CYP2B6 preferentially metabolizes NNK. In contrast to CYP2A6, CYP2B6 has a low affinity for 
nicotine [8] and makes a minor contribution to systemic nicotine metabolism (<20%) and 
characterized gene variants are not associated with differences in cigarette consumption [10,11]. 
Consequently, CYP2B6 gene variants are biologically positioned to influence the risk of developing 
lung cancer among cigarette smokers through altered metabolic activation of nitrosamines (potentially 
within the lung) as opposed to indirectly through cigarette consumption.  
Here, we present a feasibility study of genetic variation in CYP2B6 as a potential lung cancer risk 
factor. To propose a role for CYP2B6 gene variants and altered nitrosamine activation, it was critical to 
assess whether CYP2B6 operated independently of CYP2A6 to influence lung cancer risk among 
smokers. The CYP2B6 and CYP2A6 genes are located in proximity on chromosome 19q23 with their 5' 
regulatory regions oriented towards each other [12,13], and reports of genetic linkage, co-regulation 
and correlated liver expression levels [11–14] coupled with the common role of these enzymes as 
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activators of TSNAs suggested a potential redundant role of CYP2B6 and CYP2A6 gene variants. In 
this exploratory analysis, our main objectives were to estimate the effect size of CYP2B6 relative to 
CYP2A6 and CHRNA5-A3-B4 and to establish a probable independent contribution of CYP2B6 to the 
risk of lung cancer among smokers and in so doing implicate a role for altered nitrosamine activation 
in the molecular mechanism of lung carcinogenesis. 
2. Results and Discussion 
CYP2B6 genotype frequencies did not deviate from the Hardy-Weinberg equilibrium overall, in 
controls or in cases. We found the CYP2B6*6 haplotype and the CYP2B6*4 and *9 alleles at a 
frequency of 24%, 2.5% and 0%, respectively, in control subjects, which is consistent with other study 
samples of European descent [15,16]. Less than five percent (n = 41) of the 860 participants from the 
original study possessed the CYP2B6*4 allele in isolation precluding an independent investigation of 
this allele, and thus were excluded from analyses. Table 1 summarizes the characteristics and 
CYP2B6*6 genotyping results of the 819 study participants included in analyses.  
Table 1. Characteristics of study subjects and genotyping results. 
 Cases, n = 398 Controls, n = 421 p value 
Mean Age (sd) 61.9 (10.7) 61.4 (7.4) 0.20 
Sex, n (%)    
Male 236 (59) 246 (58) 0.80 
Female 162 (41) 175 (42)  
Smoking Status, n (%)    
Current 206 (52) 196 (47) 0.14 
Former 192 (48) 225 (53)  
FTND nicotine dependence score (sd) a  4.81 (2.28) 4.81 (2.56) 0.96 
No. cigarettes per day (sd) 27.4 (13.2) 26.8 (14.6) 0.27 
Years smoked (sd) 36.9 (12.3) 35.6 (11.8) 0.22 
CYP2B6*6 genotyping, n (%)    
*1/*1 221 (56) 240 (57) 0.71 
*1/*6 157 (39) 156 (37)  
*6/*6 20 (5) 25 (6)  
CYP2A6 genotype groups b, n (%)    
CYP2A6 NM (normal metabolizer) 326 (82) 327 (78) 0.13 
CYP2A6 RM (reduced metabolizer) 72 (18) 94 (22)  
CHRNA5-A3-B4 genotype groups c, n (%)    
A5-A3-B4 GG or GA 330 (83) 372 (88) 0.03 
A5-A3-B4 AA 68 (17) 49 (12)  
sd: standard deviation; a FTND scores missing for 4 cases and 2 controls; b CYP2A6 RMs are those 
individuals with one or more reduced/null activity alleles (CYP2A6*2, *4, *9, *12), while CYP2A6 NMs 
have none of the alleles for which we genotyped; c CHRNA5-A3-B4 genotype represented by tag SNP 
rs1051730 G>A with the highest risk genotype for smoking intensity and lung cancer risk kept separate.  
p values were calculated with a chi-square test for categorical variables and a Wilcoxon ranksum test for 
continuous variables. 
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To assess the genetic risk for developing lung cancer, participants were separated into a high- and 
low-risk genotype group for each gene. We employed the same high- vs. low-risk lung cancer 
genotype groups for CYP2A6 and for CHRNA5-A3-B4 as before (Table 1): CYP2A6 normal vs. 
reduced metabolizers (those who possess at least one reduced activity allele) and CHRNA5-A3-B4 AA 
vs. GG/GA [1]. For CYP2B6, the CYP2B6*6 haplotype appeared to act recessively whereby only those 
homozygous for the CYP2B6*6 allele were afforded protection from lung cancer risk. Hence, 
participants with the CYP2B6*1/*1 and CYP2B6*1/*6 genotypes were pooled together into the high-risk 
group, while participants with the CYP2B6*6/*6 genotype comprised the low-risk group. The effect of 
the CYP2B6*6 variant allele relative to the CYP2B6*1 wildtype allele on the enzymatic activation of 
TSNAs has not yet been characterized. Our findings appear to be similar to the effects of CYP2B6*6 on 
the well-characterized CYP2B6 substrate efavirenz where a reduction in in vitro and in vivo metabolism 
and a higher incidence of side effects were only evident with the CYP2B6*6/*6 genotype [17–19]. The 
CYP2B6*6 allele is associated with reduced protein expression [11,20]—perhaps a substantial reduction 
in CYP2B6 protein (i.e., CYP2B6*6/*6) is necessary to influence lung cancer risk.  
Figure 1A presents lung cancer odds ratios for each gene alone with the low-risk genotype group 
serving as the reference group. Of note, the odds ratios for CYP2B6 and CYP2A6 were of similar 
magnitude, although the associations did not reach statistical significance. The odds ratio conferred by the 
CYP2B6*6 genotype is unlikely to be driven through an indirect association with CYP2A6 gene variants: 
we found no significant correlations between CYP2A6 and CYP2B6 gene variants (r2 = 0.00–0.01 for 
each pairwise comparison) when we investigated linkage disequilibrium using Haploview (v4.2) [21]. 
Furthermore, when we concurrently evaluated all three genes in a multivariate logistic regression 
model there was a negligible shift in the odds ratio for each gene (1.25 to 1.25 for CYP2B6; 1.27 to 
1.26 for CYP2A6; 1.56 to 1.55 for CHRNA5-A3-B4) suggesting that variation in each gene is 
contributing independently to the risk of lung cancer. 
Combined gene analyses provided additional evidence that CYP2B6 was contributing independently 
to cancer risk. We first evaluated each gene pair by comparing participants possessing both high-risk 
genotypes to those with both low-risk genotypes (Figure 1B). For example, individuals in both the 
CYP2B6 and CYP2A6 high-risk genotype groups (CYP2B6 *1/*1, *1/*6 and CYP2A6 normal 
metabolizer) were compared to those in both low-risk genotype groups (CYP2B6 *6/*6 and CYP2A6 
reduced metabolizer). Larger odds ratio for CYP2B6 and CYP2A6 in combination relative to either 
gene alone suggests that variation in these genes independently and additively contribute to lung 
cancer risk possibly through preferential enzymatic activation of distinct TSNAs—CYP2B6 has a high 
affinity for NNK, whereas CYP2A6 has a high affinity for NNN [8,9]. Comparable odds ratios for the 
combination of CHRNA5-A3-B4 with either CYP2B6 or CYP2A6 is also of note and may suggest that 
concomitant variation in a nicotine/nitrosamine pharmacokinetic and pharmacodynamic gene confers a 
consistent degree of lung cancer risk.  
Combined variation in both CYP2B6 and CYP2A6 appeared to confer a greater increase in lung 
cancer risk (odds ratio of ~3.00) compared to variation in either CYP2B6 or CYP2A6 paired with 
variation in CHRNA5-A3-B4 (odds ratio of ~2.00). Similarly high odds ratio have been reported for the 
combined effect of variation in two genes encoding enzymatic activators of polycyclic aromatic 
hydrocarbons, MPO and CYP1A1 (odds ratio of 2.88) [22]. Genetic variation in multiple 
pharmacokinetic genes, particularly if activating different procarcinogens, presumably increases the 
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load of activated procarcinogens from cigarette smoke leading to increased DNA adducts and perhaps 
an increased occurrence of DNA mutations that result in cellular transformation. While there have 
been numerous studies on the association of gene variants within cigarette smoke pharmacokinetic 
pathways and lung cancer, less is known regarding variation in pharmacodynamic pathways such as 
nicotinic receptor signaling, and it remains to be determined whether the combination of gene variants 
within pharmacokinetic and dynamic pathways will confer a degree of risk similar to that observed in 
this study.  
Figure 1. (a) Lung cancer risk by CYP2B6, CYP2A6 and CHRNA5-A3-B4 genotype group 
for each gene alone (p = 0.47, 0.17 and 0.03); (b) each gene pair in combination (p = 0.18, 
0.06 and 0.01); (c) all three genes in combination where participants were classified as 
having 0, 1, 2 or 3 high-risk genotypes and those with 0 high-risk genotypes served as the 
reference group (p = 0.40, 0.29 and 0.11); and (d) in the lighter-smoking stratum, cigarettes 
per day ≤ 20 (p = 0.39, 0.03 and 0.14). All odds ratios were determined by logistic 
regression modeling and adjusted for age, gender and log pack-years. Genotype 
comparisons were as follows: CYP2B6 *1/*1, *1/*6 vs. *6/*6, CYP2A6 normal vs. reduced 
metabolizer, CHRNA5-A3-B4 AA vs. GG/GA. * p ≤ 0.05. Refer to Supplementary  
Tables S1–S4 for subject numbers and unadjusted and adjusted lung cancer odds ratios for 
Figure 1A–D, respectively. 
 
The combined impact of variation in all three genes is presented in Figure 1C. We separated 
individuals into four groups based on the number of high-risk genotypes that they possessed: those 
with none of the high-risk genotypes (0 risk), any one (1 risk), any two (2 risk), or all three high-risk 
genotypes (3 risk). The 0 risk group served as the reference group. The odds ratios increased in 
magnitude with each increase in the number of high-risk genotypes. A post-estimation Wald test for 
homogeneity between the combined genotype groups (p = 0.06) also suggests that separating  
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ever-smokers by their combined CYP2B6/CYP2A6/CHRNA5-A3-B4 genotypes stratified them by their 
risk for developing lung cancer.  
To gain further insight into the mechanisms by which these gene variants could be contributing to 
lung cancer risk within the context of smoking, we performed subgroups analyses by daily cigarette 
use and by years of smoking. We previously noted that the impact of CYP2A6 gene variants was 
greater on lung cancer risk in the lighter-smoking half of this study population (cigarettes per day  
≤20) [1]. We again performed a median split based on cigarette consumption (cigarettes/day  
≤20 vs. >20) and findings in the lighter-smoking stratum are presented in Figure 1D. Similar to 
CYP2A6, the impact (odds ratio) of CYP2B6 was larger in the lighter-smoking stratum although it was 
not statistically significant. When we concurrently evaluated all three genes in a multivariate logistic 
regression model there was a negligible shift in the odds ratio for each gene (1.54 to 1.56 for CYP2B6; 
1.65 to 1.64 for CYP2A6; 1.58 to 1.60 for CHRNA5-A3-B4) again suggesting that variation in each 
gene is contributing independently to the risk of lung cancer. Combined gene analyses also yielded 
larger odds ratios in the lighter-smoking stratum (data not shown). Gene effects at lower cigarette 
exposure have been reported for other metabolic genes such as CYP1A1, GSTM1 and MPO [23–25]. 
At high cigarette (carcinogen) exposure, subtle differences in nitrosamine activation based on genotype 
may be difficult to detect [26]. Of note, mean daily cigarette consumption within the lighter-smoking 
stratum was 16.6, which is similar to the reported mean of 15.1 among daily smokers in the US in 
2010 [27]. Thus, risk estimates and risk factors among the lighter-smoking stratum in our study 
population are relevant to present day smoking habits.  
We also performed a median split by smoking duration (years of smoking ≤38 vs. >38) to gain 
insight into the temporal relationship between genetic risk factors and carcinogenesis (data not shown). 
We observed nominally larger odds ratios for CHRNA5-A3-B4 in the shorter- vs. longer-duration 
stratum, 1.66 vs. 1.27, consistent with the association of variation in this chromosomal region with an 
earlier age of cancer onset [28]. For CYP2B6 and CYP2A6, we observed nominally larger odds ratios 
in the longer- vs. shorter-duration stratum, 2.05 vs. 0.75 and 1.66 vs. 1.03, respectively. Both enzymes 
activate nitrosamines into reactive species capable of forming DNA adducts [2,6,8] and perhaps larger 
odds ratios in the longer-duration stratum reflect increasing cancer risk through an accumulation  
of carcinogenesis-promoting genotoxic events. The influence of CYP2B6 genotype group among  
those smoking for a longer duration appeared to be relatively larger than for CYP2A6 genotype  
group. However, it bears noting that this genetic association study was not powered for multiple 
subgroups analyses. 
Based on our results implicating CYP2B6 and CYP2A6 gene variants with the risk of developing 
lung cancer risk among smokers, we hypothesize that altered nitrosamine enzymatic activation 
contributes to the molecular mechanism of lung carcinogenesis. Evidence corroborating our 
interpretation include human data demonstrating that CYP2A6 inhibition in cigarette smokers was 
associated with reduced activation of NNK as indicated by the increased routing of NNK to the 
metabolite NNAL [29], and by mouse data demonstrating that inhibition of mouse CYP2A enzymes 
reduced the occurrence of NNK-induced adenomas [30]. Variation in CYP2A13 may also contribute to 
differences in nitrosamine activation and resulting cancer risk among cigarette smokers—CYP2A13 is 
predominantly expressed in the respiratory tract and, like CYP2B6, has a high affinity for NNK while 
playing a negligible role in peripheral nicotine metabolism [31,32]. A number of CYP2A13 gene 
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variants have been discovered [33], and the CYP2A13*2 allele was associated with lung cancer risk 
among Chinese [34]. CYP2A13 was not genotyped within this sample due to the low prevalence of 
gene variants among European Americans [33]. 
There are a number of limitations to this study that are inherent to most genetic association studies 
investigating cancer risk. For example, odds ratio adjustments for cigarette exposure relied on cigarette 
pack-years, which was derived from self-reported average daily cigarette consumption and years of 
smoking and may not adequately capture inter-individual differences in carcinogen exposure over 
time. Statistical power was also a limitation, as anticipated based on results from our previous 
investigation of CYP2A6, which only reached significance in the lighter-smoking stratum [1]. 
Assuming a comparable effect size for CYP2B6, even analyses within the lighter-smoking stratum 
would be underpowered due to the smaller size of the reference CYP2B6 genotype group, 
CYP2B6*6/*6. Thus, reported findings were meant to be mainly investigative (hypothesis generating) 
in nature but strongly support further investigation of CYP2B6, particularly in smoking populations 
characterized by a higher prevalence of CYP2B6 gene variants and by lighter-smoking, such as African 
Americans and Alaska Native people [15,35]. Both African American and Alaska Native smokers 
experience more difficulty quitting despite lower cigarette consumption [36–39], and it was among the 
longer-duration and lighter-smokers where we observed larger odds ratio for CYP2B6 and CYP2A6. 
Among these populations, which have a disproportionately high lung cancer risk [40,41], CYP2B6 
genotype may facilitate the identification of sub-groups of smokers at higher and lower cancer risk. 
3. Experimental Section  
We investigated the association of CYP2B6 gene variants with lung cancer risk in the case-control 
population in which we previously investigated CYP2A6 and CHRNA5-A3-B4 [1] enabling us to 
account for the influence of CYP2A6 and CHRNA5-A3-B4, which we already knew to be associated 
with both cigarette consumption and lung cancer risk. Briefly, all study participants were current or 
former smokers of European descent. Healthy control subjects were frequency matched to non-small 
cell lung cancer case subjects by age, gender and smoking variables [1]. This study was approved by 
Review Boards at the M.D. Anderson Cancer Center (Houston, TX, USA) and the University of 
Toronto (Toronto, ON, Canada). 
For the current analyses, we genotyped participants for the CYP2B6*6 allele, a haplotype defined 
by the co-occurrence of non-synonymous single nucleotide polymorphisms in exons 4 (G516T) and 5 
(A785G) [15,16]. The CYP2B6*6 PCR-based genotyping assay begins with a gene-specific 
amplification followed by a haplotype-specific amplification in which the co-occurrence of the exon 4 
and 5 variants is detected using a forward primer targeted to the exon 4 variant and a reverse primer 
targeted to the exon 5 variant [16]. The CYP2B6*6 haplotype is prevalent in all world populations 
ranging in frequency from approximately 14% to 62% [15] and is associated with reduced protein 
expression and reduced in vivo activity for a number of substrates [11,15,42]. We previously 
genotyped participants for CYP2A6 alleles with reduced activity that are common in populations of 
European descent (CYP2A6*2, *4, *9, *12) and for the SNP rs1051730 G>A, which tags the loci 
associated with both smoking and lung cancer risk within the CHRNA5-A3-B4 cluster on chromosome 
15q25.1 [1,43].  
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Odds ratios were estimated using logistic regression modeling, which permitted the concurrent 
evaluation of potential covariates such as cigarette pack-years. Reported odds ratios were adjusted for 
age, gender and log cigarette pack-years, a common proxy for cigarette exposure. We also adjusted 
odds ratios for cigarette consumption and years of smoking, separately and concurrently, but observed 
negligible shifts in the results. In all lung cancer risk analyses, the low-risk genotype group served as 
the reference group. Statistical analyses were performed with Stata Release 11 (StataCorp LP, College 
Station, TX, USA). 
4. Conclusions  
CYP2B6 gene variants are biologically positioned to influence the risk of developing lung cancer 
among cigarette smokers through altered enzymatic activation of nitrosamines. However, based on 
reports of genetic linkage and co-regulation with CYP2A6, coupled with a potential redundancy of 
function through substrate overlap, it was unclear whether CYP2B6 would influence lung cancer risk 
independently of CYP2A6. Furthermore, both enzymes are expressed within the lung and localized 
nitrosamine activation has been linked to nitrosamine-induced lung tumors [2,4,7]. 
We found evidence that variation in CYP2B6 influences lung cancer risk with a similar magnitude 
to CYP2A6 and that variation in these genes influences lung cancer risk independently. Preferential 
enzymatic activation of distinct TSNAs, NNK by CYP2B6 and NNN by CYP2A6 [8,9], may underlie 
the observed independent contributions of these genes to lung cancer risk. Combined analyses of 
concurrent variation in CYP2B6, CYP2A6 and CHRNA5-A3-B4 appeared to stratify ever-smokers by 
lung cancer risk supporting an important role for variation in both nicotine/nitrosamine 
pharmacokinetic and pharmacodynamic pathways to the risk for lung cancer among smokers.  
Based on our findings, lung cancer genetic association studies among ethnic populations with a 
higher percentage of CYP2B6 gene variants would be beneficial to validate our observations. 
Furthermore, additional animal studies modulating the expression and/or activity level of nitrosamine 
metabolizing enzymes, such as CYP2A and CYP2B, would provide valuable insight into the  
biological mechanism behind our observed differences in lung cancer risk by CYP2B6 and CYP2A6 
gene variants. 
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